ADPKD Clinical Trial
— ACTIONOfficial title:
A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study
Verified date | January 2023 |
Source | Palladio Biosciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 3 trial consisting of a 2-arm, double-blind, placebo-controlled, randomized phase (Part 1) followed by a single-arm open-label phase (Part 2) to demonstrate the efficacy and safety of lixivaptan in participants with autosomal dominant polycystic kidney disease (ADPKD). Part 1 of the trial is designed to demonstrate the efficacy of lixivaptan in slowing the decline in kidney function as measured by the difference in estimated glomerular filtration rate (eGFR) between the lixivaptan-treated and placebo-treated participants. Part 2 of the study is designed to provide confirmation of the durability of this effect. Additionally, both parts of the study will contribute to understanding the safety of lixivaptan, particularly any effects on liver chemistry tests.
Status | Terminated |
Enrollment | 12 |
Est. completion date | August 3, 2022 |
Est. primary completion date | August 3, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Diagnosis of ADPKD by appropriate imaging or genetic testing. - Mayo Clinic MRI imaging classification of 1C, 1D or 1E. - eGFR =25 mL/min/1.73 m2 and =90 mL/min/1.73 m^2. - Body mass index between 18 and 40 kg/m^2. - Control of hypertension consistent with the 2021 Kidney Disease: Improving Global Outcomes guidelines without a diuretic and with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) unless not considered medically appropriate. - Willing to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential). - Able to provide informed consent. Exclusion Criteria: - Known sensitivity or idiosyncratic reaction to lixivaptan and/or its excipients. - Hypovolemia. - Abnormal serum sodium concentration at Screening. - Subjects who have taken any investigational drug or used an investigational device within 30 days, or 5 half-lives, whichever is longer, prior to Screening. - Subjects who are taking, have taken within the past 2 weeks, or are expected to be taking, strong or moderate CYP3A4 or CYP2C8 inhibitors or inducers including regular use of grapefruit juice or Seville oranges. - Prior use of tolvaptan or lixivaptan within the past 2 months. - Prior use of conivaptan, somatostatin analogs (e.g., lanreotide, pasireotide, octreotide, etc.), metformin, nicotinamide, bardoxolone, demeclocycline, or mammalian target of rapamycin kinase inhibitors (e.g., everolimus, sirolimus, etc.), or KetoCitra™ or any beta-hydroxybutyrate containing supplements to treat ADPKD within the past 2 months. - Prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor (e.g., canagliflozin, dapagliflozin, empagliflozin, etc.) within the past 2 months or expected need for initiation of treatment with a SGLT2 inhibitor during the study. - Prior use of a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor within the past 2 months or expected need for initiation of treatment with a HIF-PH inhibitor during the study. - Requirement for ongoing diuretic use. - Advanced diabetes (e.g., glycosylated hemoglobin >7.5%, and/or glycosuria by dipstick, significant proteinuria [>300 mcg albumin/mg creatinine]), other significant kidney disease, kidney cancer, transplanted kidney, single kidney, recent kidney surgery within the past 6 months (including cyst drainage or fenestration) or acute kidney injury within past 6 months. - Clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia). - New York Heart Association Functional Class 3 or 4 heart failure or other significant cardiac or ECG findings that could pose a safety risk to the subject. - Positive test results for hepatitis B surface antigen or hepatitis C antibody. - History of infection with human immunodeficiency virus unless the participant is clinically stable and doing well on a non-CYP interacting anti-retroviral therapy (ART) regimen and who has not required more than 2 changes in their ART regimen since treatment inception. - History of clinically significant drug or alcohol abuse in the past 2 years. - Contraindications to or interference with MRI assessments. - Malignancy within the past 5 years except for those not considered to affect participant survival. - Medical history or findings that preclude safe participation in the trial or participants who are likely to be non-compliant with trial procedures in the opinion of the Investigator or medical monitor. - Clinically significant liver disease or impairment or alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin values >1.2 x ULN during Screening. Note: This criterion will preliminarily be reviewed at Visit 2 based on Visit 1a and Visit 1b results (if Visit 1b is required). The criterion must be re-evaluated no later than Visit 3 when results for Visit 2 are available. - Simvastatin at a total daily dose >10 mg or amlodipine at a total daily dose >5 mg. |
Country | Name | City | State |
---|---|---|---|
Australia | Renal Research - Gosford | Gosford | New South Wales |
Bulgaria | University Multiprofile Hospital for Active Treatment | Pleven | |
Bulgaria | Medical Center "Hipokrat - N" | Plovdiv | |
Bulgaria | University Multiprofile Hospital for Active Treatment - Kaspela | Plovdiv | |
Bulgaria | Kidney Center - Medical Center | Varna | |
Bulgaria | Multi-Profile Hospital for Active Treatment Sveta Anna - Varna | Varna | |
Hungary | Bajai Szent Rokus Korhaz | Baja | |
Hungary | Semmelweis Egyetem | Budapest | |
Hungary | Debreceni Egyetem | Debrecen | |
Hungary | Bugat Pal Korhaz | Gyöngyös | |
Hungary | University of Pecs | Pécs | |
Poland | SCM Spolka z o.o | Kraków | |
Poland | Provita Centrum Medyczne sp. z o.o. | Warsaw | |
Spain | Hospital Universitari de Bellvitge (HUB) | Barcelona | |
Spain | Hospital Universitario Fundacion Jimenez Diaz | Madrid | |
Turkey | T.R. Ministry of Health Ankara Training and Research Hospital (Internal Disease, Division of Nephrology) | Ankara | |
Turkey | Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi | Fatih | |
Turkey | Istanbul Universitesi - Cerrahpasa Tip Fakultesi Hastanesi (IUCTFH) | Fatih | |
Turkey | Erciyes Universitesi Tip Fakultesi (Erciyes University Faculty of Medicine) (Internal Medicine; Nephrology) | Kayseri | |
United Kingdom | Salford Royal NHS Foundation Trust | Salford | |
United States | JEM Research Institute | Atlantis | Florida |
United States | Northeast Clinical Research Center, LLC | Bethlehem | Pennsylvania |
United States | Tufts Medical Center, Inc, | Boston | Massachusetts |
United States | Nephrology Associates of Northern Virginia, Inc | Fairfax | Virginia |
United States | Elixia at Florida Kidney Physicians - Southeast | Fort Lauderdale | Florida |
United States | Qway Research | Hialeah | Florida |
United States | Nephrology Associates, PC - Greystone | Hoover | Alabama |
United States | Prolato Clinical Research Center (PCRC) | Houston | Texas |
United States | Nephrology Consultants, LLC | Huntsville | Alabama |
United States | Clinical Research Consultants, LLC | Kansas City | Missouri |
United States | Knoxville Kidney Center LLC | Knoxville | Tennessee |
United States | South Florida Nephrology Associates PA | Lauderdale Lakes | Florida |
United States | Total Research Group, LLC | Miami | Florida |
United States | Angel City Research, Inc | Morrisville | North Carolina |
United States | Innovation Medical Research Center, Inc | Palmetto Bay | Florida |
United States | Brown Medicine - Brown Physicians Patient Center | Riverside | Rhode Island |
United States | Mayo Clinic | Rochester | Minnesota |
United States | St Clair Nephrology Research, LLC | Roseville | Michigan |
United States | Utah Kidney Research Institute | Salt Lake City | Utah |
United States | Clinical Advancement Center, PLLC | San Antonio | Texas |
United States | Arizona Kidney Disease & Hypertension Center - Scottsdale / Pima | Scottsdale | Arizona |
United States | Florida Kidney Physicians - Tampa | Tampa | Florida |
United States | Clinical Site Partners, LLC | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
Palladio Biosciences | Centessa Pharmaceuticals plc |
United States, Australia, Bulgaria, Hungary, Poland, Spain, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Annualized Change in Estimated Glomerular Filtration Rate (eGFR) - Part 1 | The annualized change in eGFR will be calculated from the Chronic Kidney Disease Epidemiology Collaboration eGFR creatinine equation refit without the race variable (CKD-EPIcr_R) equation for serum creatinine from baseline (mean of 3 eGFR determinations obtained during Screening and Placebo Run-in Periods [Visits 1a/1b (if required), Visit 2, and Visit 3]) to final assessment (mean of 3 eGFR determinations obtained during Follow-up Period I or, for participants who discontinue treatment prior to Visit 22, during the Follow-up Period 8 to 28 days following study drug treatment discontinuation). | Baseline to the end of Follow-up Period I (up to 71 weeks) | |
Primary | Annualized Change in Estimated Glomerular Filtration Rate (eGFR) - Part 2 | The annualized change in eGFR will be calculated from the CKD-EPIcr_R equation for serum creatinine from baseline (mean of 3 eGFR determinations obtained during obtained during Follow-up Period I) to final assessment (mean of 3 eGFR determinations obtained during Follow-up Period II or, for participants who discontinue treatment prior to Visit 43, during the Follow-up Period 8 to 28 days following study drug treatment discontinuation). | Baseline to the end of Follow-up Period II (up to 64 weeks) | |
Secondary | Number of Participants With Serum Alanine Aminotransferase (ALT) Levels >3 × the Upper Limit of Normal (ULN) - Part 1 | Number of participants randomized to lixivaptan with serum ALT levels >3 × the ULN compared to those randomized to placebo. The normal range of ALT was defined as 0-33 or 0-44 U/L, depending on the lab used. | From the end of the Single-blind Lixivaptan Titration Period to the end of Follow-up Period I (maximum of 102 days) | |
Secondary | Number of Participants With Serum ALT Levels >3 × the ULN - Part 2 | Number of participants randomized to lixivaptan with serum ALT levels >3 × ULN compared to those randomized to placebo. The normal range of ALT was defined as 0-33 or 0-44 U/L, depending on the lab used. | Duration of the Lixivaptan Re-titration Period and the Maintenance Treatment Period (56 weeks) and Follow-up Period II (4 weeks) | |
Secondary | eGFR Slope - Part 1 | Annualized rate of change (slope) in eGFR for serum creatinine, based on all eGFR determinations from baseline to all visits with on-treatment eGFR values during the Double-blind, Randomized Treatment Period. The baseline value will be calculated as the mean of 3 eGFR determinations obtained during Screening and Placebo Run-in Periods (Visits 1a/1b [if required], Visit 2, and Visit 3). | Baseline to the end of Double-blind Randomized Treatment Period (up to 67 weeks), with changes from baseline calculated every 4 weeks during the Double-blind Randomized Treatment Period | |
Secondary | eGFR Slope - Part 2 | Annualized rate of change (slope) in eGFR for serum creatinine, based on all eGFR determinations from baseline to all visits with on-treatment eGFR values during the Maintenance Treatment Period. The baseline value will be calculated as the mean of 3 eGFR determinations obtained during obtained during Follow-up Period I. | Baseline to the end of the Maintenance Treatment Period (up to 60 weeks), with changes from baseline calculated every 4 weeks during the Maintenance Treatment Period | |
Secondary | Height-adjusted Total Kidney Volume (htTKV) - Part 1 | Annualized percent change in htTKV, determined by magnetic resonance imaging (MRI), from baseline (obtained at Screening [Visit 1a]) to the end of Follow-up Period I. | Baseline to the end of Follow-up Period I (up to 71 weeks) | |
Secondary | Height-adjusted Total Kidney Volume (htTKV) - Part 2 | Annualized percent change in htTKV, determined by MRI from baseline (obtained at Visit 25/Week 56) to the end of Follow-up Period II. | Baseline to the end of Follow-up Period II (up to 60 weeks) | |
Secondary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Lixivaptan Titration Period in Part 1 | Number of participants with TEAEs during the Lixivaptan Titration Period. | Up to 6 weeks | |
Secondary | Number of Participants With TEAEs After Randomization in Part 1 | Number of participants with TEAEs by treatment group after Randomization (Double-blind Randomized Treatment Period and Follow-up Period I) | From Randomization to study completion (up to 102 days) | |
Secondary | Number of Participants With TEAEs in Part 2 | Number of participants with TEAEs by treatment cohort during Part 2 (Lixivaptan Re-titration Period, Maintenance Treatment Period, and Follow-up Period II). | Up to 60 weeks | |
Secondary | Number of Participants With Potentially Clinically Important Clinical Laboratory Findings During the Lixivaptan Titration Period in Part 1 | Number of participants with clinical laboratory findings (clinical chemistry, hematology and urinalysis) recorded during the Lixivaptan Titration Period and considered to be potentially clinically important. | Up to 6 weeks | |
Secondary | Number of Participants With Potentially Clinically Important Clinical Laboratory Findings After Randomization in Part 1 | Number of participants with clinical laboratory findings (clinical chemistry, hematology and urinalysis) recorded after Randomization (Double-blind Randomized Treatment Period and Follow-up Period I) and considered to be potentially clinically important, by treatment group. | From Randomization to last clinical laboratory evaluation (up to 102 days) | |
Secondary | Number of Participants With Potentially Clinically Important Clinical Laboratory Findings in Part 2 | Number of participants with clinical laboratory findings (clinical chemistry, hematology and urinalysis) recorded during Part 2 (Lixivaptan Re-titration Period, Maintenance Treatment Period, and Follow-up Period II) and considered to be potentially clinically important, by treatment cohort. | Up to 60 weeks | |
Secondary | Number of Participants With Potentially Clinically Important Vital Signs Findings During the Lixivaptan Titration Period in Part 1 | Number of participants with vital signs findings (heart rate, diastolic and systolic blood pressure, weight) recorded during the Lixivaptan Titration Period and considered to be potentially clinically important. | Up to 6 weeks | |
Secondary | Number of Participants With Potentially Clinically Important Vital Signs Findings After Randomization in Part 1 | Number of participants with vital signs findings (heart rate, diastolic and systolic blood pressure, weight) recorded after Randomization (Double-blind Randomized Treatment Period and Follow-up Period I) and considered to be potentially clinically important, by treatment group. | From Randomization to last measurement of vital signs (up to 102 days) | |
Secondary | Number of Participants With Potentially Clinically Important Vital Signs Findings in Part 2 | Number of participants with vital signs findings (heart rate, diastolic and systolic blood pressure, weight) recorded during Part 2 (Lixivaptan Re-titration Period, Maintenance Treatment Period, and Follow-up Period II) and considered to be potentially clinically important, by treatment cohort. | Up to 60 weeks | |
Secondary | Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Findings During the Lixivaptan Titration Period in Part 1 | Number of participants with ECG findings recorded during the Lixivaptan Titration Period and considered to be potentially clinically important (defined as a QT interval corrected for heart rate according to Fridericia's formula [QTcF] = 450 msec). | Up to 6 weeks | |
Secondary | Number of Participants With Potentially Clinically Significant 12-lead ECG Findings After Randomization in Part 1 | Number of participants with ECG findings recorded after Randomization (Double-blind Randomized Treatment Period and Follow-up Period I) and considered to be potentially clinically important (defined as a QTcF = 450 msec), by treatment group. | From Randomization to last ECG (up to 102 days) | |
Secondary | Number of Participants With Potentially Clinically Significant 12-lead ECG Findings in Part 2 | Number of participants with ECG findings recorded during Part 2 (Lixivaptan Re-titration Period, Maintenance Treatment Period, and Follow-up Period II) and considered to be potentially clinically important (defined as a QTcF = 450 msec), by treatment cohort. | Up to 60 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT02776241 -
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Terminated |
NCT04152837 -
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
Recruiting |
NCT04338048 -
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
|
||
Not yet recruiting |
NCT06100133 -
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
|
Phase 2 | |
Completed |
NCT01632605 -
The Vienna RAP Pilot Study
|
N/A | |
Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
Not yet recruiting |
NCT05373264 -
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
|
Phase 3 | |
Recruiting |
NCT06085807 -
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
|
||
Completed |
NCT01853553 -
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Completed |
NCT04472624 -
Short Term Induction of Ketosis in PKD
|
N/A | |
Not yet recruiting |
NCT03764605 -
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT04680780 -
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
Completed |
NCT02161068 -
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
|
||
Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |